接受根治性或新辅助放(化)疗的老年(≥70岁)食管癌患者的临床结局:一项回顾性单中心分析
该回顾性单中心分析纳入1999至2015年接受根治性放(化)疗的55例老年(≥70岁)食管癌患者,中位年龄75岁,多数为局部晚期(T3/4占78%,N+占58%)且为鳞癌(74%)。全组1年和2年局部区域控制率分别为60%和45%,总生存率分别为46%和26%;最大放(化)疗相关3级及以上毒性发生率为80%,包括7例死亡(13%)。作者认为根治性放(化)疗在老年患者中可能带来显著毒性和不佳结局,但2008年后治疗的患者结局明显改善,可能归因于更好的患者选择。
要点
- 全组1年和2年局部区域控制率分别为60%和45%,总生存率分别为46%和26%。
- 放(化)疗相关3级及以上毒性发生率为80%,包括7例(13%)治疗相关死亡。
- 5级毒性与Charlson评分(CS>1为33% vs CS≤1为5%)和治疗时期(2008年前24% vs 2008年后3%)显著相关。
核心结论
- 老年食管癌患者接受根治性放(化)疗可能产生显著毒性和不佳结局。
- 本队列中观察到随时间推移的明显改善,可能基于患者选择的优化。
- 对于分期较早且合并症较少的患者,采用现代分期和治疗手段似乎可获得与年轻队列相似的结果。
- 年龄本身不应成为决定性因素,但应仔细关注患者选择,包括结构化且严密的随访策略。
研究设计与样本
- 回顾性单中心分析纳入1999至2015年接受根治性放(化)疗的55例老年(≥70岁)食管癌患者,中位年龄75岁。
- 多数患者为局部晚期(T3/4占78%,N+占58%),鳞癌占74%,Charlson合并症评分>1者占27%。
- 48例(87%)接受根治性治疗,7例接受新辅助治疗;放疗采用三维适形或调强放疗,85%接受同步化疗(主要为顺铂/5-FU或丝裂霉素/5-FU),65%使用18FDG-PET/CT分期。
主要发现
- 中位随访11个月(范围1-68),生存者中位随访21个月。
- 全组1年和2年局部区域控制率分别为60%和45%,无远处转移控制率分别为81%和72%,无失败治疗生存率分别为55%和41%,总生存率分别为46%和26%。
- 单因素分析中,联合手术与局部区域控制率和无失败治疗生存率改善相关,淋巴结阳性与无远处转移控制率改善相关,较低T分期、较低Charlson评分和使用PET-CT与总生存率改善相关。
- 多因素分析中,较低T分期和较低Charlson评分对总生存率仍有显著意义。
- 2008年后治疗的患者1年无失败治疗生存率(64% vs 35%)和1年总生存率(66% vs 24%)显著改善。
关键数值与推荐
- 最大放(化)疗相关3级及以上毒性发生率为80%,包括7例死亡(13%)。
- 5级毒性与Charlson评分显著相关(CS>1为33% vs CS≤1为5%),也与治疗时期显著相关(2008年前24% vs 2008年后3%)。
- 2008年后治疗的患者中鳞癌显著更多、T4期更少、PET-CT分期比例更高,且照射野长度更小;Charlson评分更低和IMRT使用增加的趋势也被观察到。
临床怎么用
- 作者认为年龄本身不应成为决定性因素,但应仔细关注患者选择,包括结构化且严密的随访策略。
- 作者指出对于分期较早且合并症较少的患者,采用现代分期和治疗手段似乎可获得与年轻队列相似的结果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To analyse the outcome of elderly patients (≥70 years) with esophageal cancer treated with curative intent radio(chemo)therapy. METHODS: Fifty five patients (median 75 years) receiving curative intent radio(chemo)therapy for esophageal cancer from 1999 to 2015 were retrospectively analyzed. Most patients showed locally advanced disease (T3/4:78%, N+:58%) with squamous cell histology (74%). Charlson comorbidity score was > 1 in 27%. 48 patients (87%) received definitive treatment while 7 patients were treated neoadjuvantly. RT was carried out as 3D-conformal treatment or IMRT. Concurrent chemotherapy was applied in 85%, mainly cisplatin/5-FU or mitomycin/5-FU. 18FDG-PET/CT staging was used in 65%. RESULTS: Median follow-up was 11 months (1-68) and 21 months in survivors. 1- and 2-year rates of LRC, DC, FFTF and OS were 60%/45, 81%/72, 55%/41 and 46%/26% for the entire cohort. In univariate analysis, addition of surgery was associated with improved LRC and FFTF, nodal involvement with improved DC and lower T stage, lower Charlson score and use of PET-CT with improved OS. In multivariate analysis, lower T stage and lower Charlson score remained significant for OS. Patients treated after 2008 showed a significantly improved FFTF (1-year FFTF 64% vs 35%) and OS (1-year OS 66% vs 24%). Maximum (chemo)radiation related grade3+ toxicity was observed in 80% including 7 deaths (13%). Grade5 toxicity was significantly associated with Charlson score (CS > 1:33% vs CS ≤ 1:5%) and treatment period (24% before vs 3% after 2008). The patients treated after 2008 included significantly more SCCs, less T4 stages, had a higher percentage of PET-CT staging and were treated with smaller field lengths. Trends were also observed for lower Charlson scores and increased use of IMRT. CONCLUSION: Curative intent (chemo)radiation of elderly patients with esophageal cancer may result in considerable toxicity and unfavorable outcome. However, a clear improvement over time was observed in our cohort, probably based on improved patient selection. In patients with less advanced stages and lower comorbidity similar results as in younger cohorts seem achievable with modern staging and treatment approaches. Age per se should not be a decisive factor, but careful attention should be paid regarding patient selection including a structured and tight follow-up strategy.
引用
- Walter F, Böckle D, Schmidt-Hegemann NS, et al. Clinical outcome of elderly patients (≥ 70 years) with esophageal cancer undergoing definitive or neoadjuvant radio(chemo)therapy: a retrospective single center analysis. Radiat Oncol. 2018. PMID: 29769143. doi:10.1186/s13014-018-1044-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。